β-内酰胺类过敏对脓毒症患者死亡结局的影响评估
该单中心回顾性队列研究在肯塔基州中部一家35张床位的急诊科进行,纳入2016年10月至2017年6月期间年龄≥18岁的脓毒症患者,共识别438例严重脓毒症和/或脓毒性休克患者。报告β-内酰胺类过敏的患者院内死亡或转临终关怀复合终点发生率为7.2%,无β-内酰胺类过敏者为10.4%,差异无统计学意义(p=0.41)。β-内酰胺类过敏组抗生素启动时间2.2小时,无过敏组2.15小时,差异无统计学意义(p=0.993)。无β-内酰胺类过敏报告的患者接受适当经验性抗生素的可能性高20.9%(p=0.009),且β-内酰胺类过敏组有效治疗延迟1.59小时(p=0.037)。作者认为,充分的β-内酰胺类过敏记录对于确保严重脓毒症和脓毒性休克患者及时、适当的治疗至关重要。
要点
- 报告β-内酰胺类过敏的严重脓毒症/脓毒性休克患者,有效抗生素治疗延迟1.59小时(p=0.037)。
- 无β-内酰胺类过敏报告的患者接受适当经验性抗生素的可能性高20.9%(p=0.009)。
- β-内酰胺类过敏组与无过敏组院内死亡或转临终关怀复合终点发生率分别为7.2% vs 10.4%,差异无统计学意义(p=0.41)。
- 两组抗生素启动时间分别为2.2小时 vs 2.15小时,差异无统计学意义(p=0.993)。
- 作者认为,充分的β-内酰胺类过敏记录对确保严重脓毒症和脓毒性休克患者及时、适当的治疗至关重要。
适用人群与场景
- 2016年10月至2017年6月在肯塔基州中部一家35张床位的急诊科就诊、年龄≥18岁的脓毒症患者,共438例严重脓毒症和/或脓毒性休克患者。
研究设计与关键结果
- 单中心回顾性队列研究,纳入438例严重脓毒症和/或脓毒性休克患者,比较报告β-内酰胺类过敏与无报告者的结局。
- 主要复合终点(院内死亡或转临终关怀)发生率:β-内酰胺类过敏组7.2% vs 无过敏组10.4%,p=0.41,差异无统计学意义。
- 抗生素启动时间:β-内酰胺类过敏组2.2小时 vs 无过敏组2.15小时,p=0.993,差异无统计学意义。
- 无β-内酰胺类过敏报告的患者接受适当经验性抗生素的可能性高20.9%(p=0.009)。
- β-内酰胺类过敏组有效治疗延迟1.59小时(p=0.037)。
证据类型、等级与局限
- 证据类型:单中心回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,充分的β-内酰胺类过敏记录对于确保严重脓毒症和脓毒性休克患者及时、适当的治疗至关重要。
- 作者指出,选择替代治疗方案导致有效抗生素使用时间增加、初始抗生素覆盖培养菌的可能性降低,并增加总住院费用和可变直接成本。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To determine the impact of reported beta-lactam allergies on in-hospital mortality and other clinical outcomes in patients who presented with severe sepsis or septic shock.
METHODS: This single-center, retrospective cohort study was performed at a 35-bed emergency department in central Kentucky. Patients presenting with sepsis, aged 18years or older, were identified between October 2016 and June 2017.
RESULTS: 438 patients with severe sepsis and/or septic shock were identified. Rates of the combined endpoint of in-hospital mortality or transfer to hospice were similar in patients with a beta-lactam allergy (7.2%) versus those with no reported beta-lactam allergy (10.4%) (p=0.41). Time to initiation of antibiotic therapy was slightly longer in the beta-lactam allergic group (2.2h) versus those with no reported beta-lactam allergy (2.15h), but the difference was not statistically significant (p=0.993). Patients were 20.9% more likely to receive an appropriate empiric antibiotic, based off of retrospective culture review, if they did not report a beta-lactam allergy (p=0.009). This led to a delay in effective therapy of 1.59h in the reported beta-lactam allergy arm (p=0.037).
CONCLUSIONS: Adequate documentation of beta-lactam allergies is vital to ensure timely and appropriate treatment in patients presenting with severe sepsis and septic shock. Choosing alternative treatment options results in increased time to effective antibiotics, reduced likelihood of covering cultures with first antibiotic, and increased total hospital and variable direct cost.
参考来源
- Komyathy KL, Judd WR, Ratliff PD, et al. Assessing mortality outcomes of beta-lactam-allergic patients presenting with sepsis. Am J Emerg Med. 2020. PMID: 32738475. doi:10.1016/j.ajem.2020.05.032
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。